Sign in
Taking people in United StatesNo phase

Eye movement patterns in people taking long-term psychiatric medications, measured with the Gaize device

Studies whether an eye-tracking device can detect psychiatric medication use in adults.

Key facts

Who runs it
Gaize
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
Status
Recruiting
People taking part
50 people, planned
Started
17 Apr 2024
Expected to end
Aug 2028
Type of study
Observational, 2 groups
Treatments tested
  • Prescription Psychotropic Medications
Record updated
5 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 who have taken a prescribed psychiatric medication for more than 3 months. It tests eye movements with the Gaize device.

Age
18 to 65 years
Sex
All sexes
Earlier treatment
Must currently be taking a psychiatric medication prescribed by a healthcare professional for longer than 3 months.

Main reasons for not taking part

  • Pregnancy
  • Another clinical trial within 30 days before the study
  • Eye problems such as glaucoma, macular degeneration, cataracts, lazy eye, optic neuritis, unequal pupil size, or clinical blindness
  • Past or current head injury or traumatic brain injury
  • Photosensitive epilepsy or a history of severe motion sickness in VR

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adults aged between 18 and 65, having given written informed consent to participate in the research trial
  • Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months
  • Normal or corrected to normal vision using either glasses or contact lenses, or surgery

Who cannot take part

  • Enrolled in, or participated in another clinical trial within 30 days before the study
  • Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days
  • Had your eyes dilated by a medical doctor in the previous 24 hours
  • Photosensitive epilepsy
  • Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded
  • Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications
  • History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well
  • Diagnosed with clinical blindness
  • Current or past head inject/ traumatic brain injury (TBI)
  • Potential participants who are unable to provide consent for the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • GaizePhiladelphia, United StatesContact: Apurva Raje Research Coordinator / Principal InvestigatorTaking people

About the trial

What the trial wants to find out

The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.

The 2 groups in the trial

  • Experimental Group

    Participants will be recruited through local participants. Local psychiatrists will be enlisted to inform eligible patients about the research. Psychiatrists will disseminate information via study flyers displayed in their offices and through direct conversation with patients during appointments. This approach ensures informed and voluntary participation from individuals familiar with the psychiatric medication regimen, aligning with ethical research practices and privacy regulations. Potential participants' eligibility will be assessed based on predefined inclusion and exclusion criteria. If individuals meet these criteria and express interest, they will be provided with information about the study's objectives, potential risks, and benefits.

    Treatment: Prescription Psychotropic Medications

  • Control Group

    We will recruit control group participants by posting up flyers to the general population through community bulletin boards, social media, and local community health centers. These participants will be matched to our patient group by age, sex, and other relevant demographic factors but will not be taking psychotropic medications. Interested individuals will undergo a screening process to ensure they meet the specific criteria for the control group. To maintain transparency and informed consent, all participants, both in the study and control groups, will receive consent forms. Those willing to participate will have the opportunity to review and sign these forms.

    Treatment: Prescription Psychotropic Medications

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Observational Study to Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
Plain-language title
Eye movement patterns in people taking long-term psychiatric medications, measured with the Gaize deviceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07389473, who can take part
Record updated
5 February 2026